InterMune Inc. (ITMN) announced after the close Tuesday that Health Canada has approved Esbriet for the treatment of mild to moderate idiopathic pulmonary fibrosis in adult patients. The stock is now up 0.30 on 24K shares.
InterMune traded in a range for the majority of Tuesday's session and closed down by 0.21 at $8.85. The stock closed testing the lower end of a 2 1/2 week range.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.